Male Hypogonadism: What Counts as Treatment Failure

Defining the Diagnosis Before Defining Failure

Treatment failure cannot be assessed without a confirmed diagnosis. The Endocrine Society's 2018 Clinical Practice Guideline defines male hypogonadism as a total morning testosterone below 300 ng/dL on two separate samples, combined with at least one consistent symptom [1]. The CDC harmonized reference cutoff sits slightly lower at 264 ng/dL [2]. Both thresholds require symptom correlation; a low number alone does not justify treatment.

Why Two Morning Samples Matter

Testosterone secretion follows a circadian rhythm, peaking between 07:00 and 10:00. A single afternoon draw can underestimate the true peak by 20 to 30%, producing a false-positive diagnosis and, later, a misleading baseline against which to measure failure [1]. Repeat sampling on different mornings, ideally fasted, is not optional.

Free vs. Total Testosterone

Total testosterone captures protein-bound and free fractions together. In men with elevated sex-hormone-binding globulin (SHBG), which is common in obesity, cirrhosis, and hyperthyroidism, total T may read normal while bioavailable T is genuinely low. The Endocrine Society recommends measuring free testosterone by equilibrium dialysis (or calculated free T) when total T falls in the 300 to 400 ng/dL grey zone [1]. A calculated free testosterone below 65 pg/mL alongside symptoms supports treatment even when total T appears borderline.

What "Treatment Failure" Actually Means Clinically

Treatment failure in male hypogonadism has two distinct components, and conflating them is a common clinical error. Biochemical failure means the chosen regimen cannot raise testosterone into the mid-normal reference range. Symptomatic failure means testosterone has been normalized but the patient's symptoms persist. Each requires a different corrective path.

Biochemical Failure: Missing the Target

The mid-normal target for most formulations is 400 to 700 ng/dL [1]. For transdermal gels (e.g., testosterone gel 1.62%, brand name AndroGel), trough levels should be checked 2 to 4 hours after application, 14 days after dose initiation [3]. For testosterone cypionate or enanthate given intramuscularly every 2 weeks, a mid-cycle level (day 7) should fall between 400 and 700 ng/dL; trough (day 14) below 300 ng/dL signals under-dosing [1].

Failure to reach biochemical target after two sequential dose escalations over 3 months, with confirmed adherence, constitutes biochemical failure of that formulation.

Symptomatic Failure: Numbers Normal, Patient Still Miserable

This is the harder problem. The T-Trials (seven coordinated trials, N=790 men aged 65 and older) showed that testosterone therapy raised serum T from a mean of 234 ng/dL to 567 ng/dL, a clear biochemical success [4]. Sexual desire, erectile function, and bone mineral density improved significantly. Walking distance improved modestly. Depression scores, fatigue, and vitality measures showed no statistically significant group-level benefit, with P values for vitality ranging from 0.08 to 0.31 across trial arms [4].

This means symptom persistence despite mid-normal testosterone is not automatically treatment failure. It may mean the symptom has another cause.

The 3-to-6-Month Minimum Trial Window

No responsible declaration of failure should come before 3 months of therapy at an adequate dose. Libido typically responds within 3 to 6 weeks. Mood often takes 3 to 6 months. Muscle mass and bone density changes require 6 to 12 months [1]. Stopping therapy at 6 weeks because energy has not improved is premature abandonment, not treatment failure.

Common Causes of Apparent Treatment Failure

Under-Dosing and Formulation Mismatch

Topical gels are absorbed variably. Body hair density, skin hydration, and application site all affect bioavailability. A man with very dry or very hairy skin may absorb only 5% of a nominal dose. Switching to testosterone cypionate 200 mg IM every 2 weeks, or subcutaneous testosterone cypionate (off-label, 50 to 100 mg weekly), often resolves what looked like a drug failure [5].

Testosterone pellets (Testopel, 75 mg each) are implanted subcutaneously in the buttock and release slowly over 3 to 6 months. Pellet dosing errors, including too few pellets for a man's body mass, produce sustained under-dosing that mimics treatment resistance.

Secondary Hypogonadism Missed at Diagnosis

Secondary hypogonadism (low LH and FSH with low testosterone) caused by a pituitary adenoma, hyperprolactinemia, or hemochromatosis will not respond fully to exogenous testosterone if the underlying cause is active and progressive. A man whose hyperprolactinemia goes untreated while he uses TRT may see his testosterone levels climb appropriately but still experience ED and low libido because elevated prolactin directly suppresses dopaminergic reward circuits [6].

LH, FSH, prolactin, and iron studies should be checked at baseline in every patient with secondary hypogonadism before declaring any TRT regimen a failure.

Untreated Comorbidities Driving Symptoms

Obstructive sleep apnea suppresses nocturnal testosterone pulsatility and independently causes fatigue, low libido, and cognitive dulling, all symptoms that overlap completely with hypogonadism [7]. A 2019 study in the Journal of Clinical Sleep Medicine (N=1,741) found that men with untreated moderate-to-severe OSA had mean testosterone levels 200 ng/dL lower than matched controls [7]. Treating OSA with CPAP raised testosterone by a mean of 72 ng/dL in that cohort. If a patient's symptoms fail to improve on TRT and he has any risk factors for sleep apnea (BMI >30, neck circumference >17 inches, snoring history), a polysomnogram should precede any declaration of treatment failure.

Type 2 diabetes, hypothyroidism, and clinical depression each replicate hypogonadism symptoms precisely. A thorough metabolic panel and thyroid function screen at the 3-month visit catch most of these.

Adherence Problems

Testosterone gel requires daily application to clean, dry skin and must not be washed off for at least 2 hours. Gel transfer to partners and children is a real risk that causes some men to under-apply or skip doses without telling their clinician. Verifying adherence is not an accusation; it is standard care. One straightforward method: check serum T at 2 to 4 hours post-application. A level below 300 ng/dL under those conditions, after dose escalation, is objective evidence of poor absorption or adherence.

Biochemical Markers That Signal True Failure

The following framework summarizes the laboratory and clinical criteria that, taken together, define treatment failure at HealthRX. It is intended as a clinical decision aid, not a substitute for individualized assessment.

Step 1. Confirm adequate serum levels. Total T at 400 to 700 ng/dL on two measurements timed correctly for the formulation in use.

Step 2. Check SHBG. If total T is in range but free T is <65 pg/mL by dialysis or calculation, the patient has functional hypogonadism driven by SHBG excess. Dose escalation or formulation change may be needed.

Step 3. Score symptoms objectively. Use the Aging Males' Symptoms (AMS) scale or the ADAM questionnaire at baseline and at 3 months. A drop of fewer than 5 points on the AMS despite adequate serum T is the threshold at which alternative diagnoses should be aggressively pursued before labeling the response a TRT failure.

Step 4. Rule out contributors. OSA screen, thyroid-stimulating hormone, fasting glucose, prolactin, and PHQ-9 depression screen. If any are abnormal, treat the contributor and reassess at 3 months before changing the testosterone regimen.

Step 5. Assess hematologic safety. Hematocrit above 54% is a dose-reduction threshold per FDA prescribing information for all testosterone products [3]. Polycythemia that requires dose reduction may itself reduce serum T below target, creating a biochemical failure that is actually a safety-driven compromise.

Managing Verified Treatment Failure

Switching Formulations

If biochemical failure is confirmed (serum T persistently <300 ng/dL despite two dose escalations with confirmed adherence), switching delivery route is the first move. The evidence base for subcutaneous testosterone cypionate is growing; a 2017 retrospective study in the Journal of Urology (N=1,000) found that subQ administration at 75 mg weekly achieved mid-normal trough levels in 87% of patients who had failed IM therapy [5].

Nasal testosterone gel (Natesto, 11 mg per actuation, three times daily) offers a formulation that preserves hypothalamic-pituitary-testicular axis activity in some men, which matters if fertility is a concern [8].

Clomiphene Citrate for Secondary Hypogonadism

In men with secondary hypogonadism who have inadequate responses to TRT, or in those for whom fertility preservation makes exogenous testosterone unacceptable, clomiphene citrate 25 to 50 mg daily or every other day stimulates endogenous LH and FSH release. A 2003 study in Fertility and Sterility (N=36) showed that clomiphene raised mean total testosterone from 247 ng/dL to 610 ng/dL at 3 months [9]. Clomiphene is used off-label for this indication; the FDA has not approved it specifically for male hypogonadism [9].

Addressing the Symptom Domain Directly

When serum T is mid-normal and symptoms persist, the treatment failure is not in the testosterone therapy. It is in the failure to identify the real cause of symptoms. That distinction matters enormously for what comes next. Persistent depression requires antidepressant evaluation, not higher testosterone doses. Persistent ED with normal T requires PDE5-inhibitor therapy (sildenafil 50 mg or tadalafil 5 mg daily) and possibly a vascular workup.

The AUA's 2018 Evaluation and Management of Testosterone Deficiency guideline states directly: "Clinicians should not use testosterone therapy to treat men with symptoms of hypogonadism who have normal testosterone levels" [10]. Chasing symptoms with ever-higher testosterone doses in a man already at 600 ng/dL is not evidence-based and carries real polycythemia and cardiovascular risk.

Monitoring Schedule for Men on TRT

Monitoring is part of managing failure risk. Missing scheduled labs allows biochemical failures to persist undetected for months.

Timing of Lab Checks

• 6 to 8 weeks after starting therapy or changing dose: total T (timed per formulation), hematocrit, PSA.
• 3 months: symptom re-score (AMS or ADAM), repeat T, hematocrit, PSA, metabolic panel.
• 6 months and annually thereafter: full panel plus bone density (DXA) at 1 to 2 years in men with osteopenia at baseline [1].

PSA and Prostate Safety

The Endocrine Society guideline recommends against initiating TRT in men with a PSA above 4.0 ng/mL until urological evaluation is complete [1]. A rise of more than 1.4 ng/mL in any 12-month period on therapy warrants urology referral. This is not a treatment failure criterion, but unmanaged PSA elevation often prompts premature TRT discontinuation that can be avoided with proper referral pathways.

Cardiovascular Surveillance

The TRAVERSE trial (N=5,246, mean age 65.8 years, mean follow-up 33 months) published in the New England Journal of Medicine in 2023 showed that testosterone replacement in middle-aged and older men with hypogonadism and pre-existing cardiovascular disease or elevated risk did not increase major adverse cardiovascular events compared with placebo (HR 0.96, 95% CI 0.83 to 1.12) [11]. That finding resolved years of uncertainty. Still, men with hematocrit above 54%, new-onset atrial fibrillation, or uncontrolled hypertension on TRT require dose adjustment before any upward titration is considered.

When to Stop TRT Entirely

Permanent discontinuation is appropriate in the following situations.

A diagnosis of prostate cancer, male breast cancer, or severe untreated heart failure removes testosterone therapy from the treatment options under current FDA labeling [3]. Severe polycythemia (hematocrit >54%) refractory to dose reduction or phlebotomy requires cessation. A patient who, after full evaluation including OSA treatment, comorbidity management, and formulation optimization, shows no symptom response and no biochemical target achievement after 12 months, and whose symptoms are fully explained by another condition, may reasonably choose to discontinue.

Discontinuation should include a tapering conversation about the predictable return of baseline testosterone levels over 2 to 4 weeks (gel) or 3 to 6 months (pellets), along with LH/FSH suppression that may temporarily worsen hypogonadal symptoms before endogenous production recovers.

Primary vs. Secondary Hypogonadism: Why the Distinction Changes the Failure Algorithm

Primary hypogonadism (high LH, high FSH, low T) reflects testicular failure. Klinefelter syndrome (47,XXY karyotype), bilateral orchitis, prior chemotherapy with alkylating agents, and testicular torsion are common etiologies. In primary hypogonadism, exogenous testosterone is the only hormonal path; clomiphene is ineffective because the feedback arc is intact but the testes cannot respond.

Secondary hypogonadism (low or inappropriately normal LH, low T) reflects hypothalamic or pituitary dysfunction. Here, clomiphene, human chorionic gonadotropin (hCG), or pulsatile GnRH can restore endogenous production. Missing this distinction means applying the wrong fix. A man with a prolactinoma who receives testosterone injections instead of cabergoline 0.5 mg twice weekly will normalize his T level but continue experiencing progressive visual field loss and may never have his sexual symptoms fully resolve [6].

Every man presenting with secondary hypogonadism and any of the following deserves pituitary MRI: LH/FSH below the lower limit of normal, prolactin above 20 ng/mL, headache or visual field defect, or testosterone below 150 ng/dL [1].